Kaiser Permanente’s corporate venturing unit has helped TriVascular, a US-based aortic disease treatment company, raise a $60m round.
Kaiser Permanente Ventures was joined leading the series D round by venture firm Redmile Group.
Venture investor New Enterprise Associates, Delphi Ventures, MPM Capital, Kearny Venture Partners and Pinnacle Ventures also took part in the round.
Sam Brasch, a director at Kaiser Permanente Ventures, will join TriVascular’s board.
Trivascular said it would use the funds to seek a US Premarket Approval Application (PMA) for its Ovation Abdominal Stent Graft System, which treats abdominal aorta aneurysms, or bulges in patients’ arteries.
TriVascular’s series C round, which raised $60m in 2010, was backed by venture firms Pinnacle Ventures, New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners.
In 2009 TriVascular raised $30m in its Series B round, backed by New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners. The company raised its A round in 2008.